AI Article Synopsis
- The article discusses a long-term study on the safety and effectiveness of etanercept, a treatment for juvenile idiopathic arthritis (JIA), in children and young adults over a span of ten years.
- JIA is an inflammatory condition that causes joint pain and stiffness, usually diagnosed before age 16, requiring ongoing treatment until the disease is in remission.
- The research highlights the need to evaluate the long-lasting safety of etanercept, which modulates the immune system to alleviate symptoms of arthritis.
Article Abstract
This is a summary of the original article 'Ten-year safety and clinical benefit from open label etanercept treatment in children and young adults with juvenile idiopathic arthritis'. Juvenile idiopathic arthritis (JIA) usually appears before the age of 16. JIA causes pain, swelling, and stiffness in the joints. People with JIA receive treatment for several years until the disease goes into prolonged remission. Therefore, the long-term safety of these treatments is an important topic. Etanercept is a treatment for JIA, which acts on the body's immune system to reduce arthritis. This summary of research article describes safety and how well etanercept works in children with JIA taking it for up to 10 years.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557797 | PMC |
| http://dx.doi.org/10.1007/s40744-024-00703-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biosimilars in pediatric rheumatology: innovations, challenges, and opportunities.
Expert Opin Biol Ther
January 2025
Department of Pediatric Rheumatology, Kocaeli University, Kocaeli, Turkey.
Article Synopsis
- Biosimilars are biologic drugs that mimic established medications for treating rheumatic diseases and become available as cost-effective alternatives once original patents expire.
- Since their introduction in pediatric rheumatology in 2013, several biosimilars have been launched, offering more treatment options for children with conditions like juvenile idiopathic arthritis.
- The article emphasizes the need for education and effective communication among healthcare providers and patients to enhance understanding and ensure proper use of biosimilars.
The Efficacy and Safety of Non-Biologic and Biologic Treatments in Palmoplantar Pustular Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
Australas J Dermatol
January 2025
King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Palmoplantar pustular psoriasis (PPPP), or palmoplantar pustulosis (PPP), is a type of psoriasis that affects the skin on the palms and soles. It is characterised by dermatosis and small sterile pustules and is considered a significant burden on patients' quality of life, as there is currently no gold standard treatment or cure. This network meta-analysis (NMA) compares the efficacy and safety of biologic and non-biologic medications for PPPP and PPP.
View Article and Find Full Text PDFAssociation between resolution of MRI-detected inflammation and improved clinical outcomes in axial spondyloarthritis under long-term anti-TNF therapy.
RMD Open
January 2025
Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Charite Universitatsmedizin Berlin, Berlin, Germany.
Objectives: In this post-hoc analysis of ESTHER trial, we aimed to investigate the longitudinal relationship between inflammation on MRI and the achievement of inactive disease/low disease activity in patients with axial spondyloarthritis (axSpA) treated with long-term tumor necrosis factor (TNF) inhibitor etanercept.
Methods: Of the 76 patients with active axSpA in the ESTHER trial, we included all patients treated with etanercept for at least 6 months for main analysis. All clinical and MRI data from 4.
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis.
Rheumatol Ther
January 2025
OPAL Rheumatology Ltd, Sydney, NSW, Australia.
Introduction: This study sought to describe treatment patterns, persistence, and effectiveness of upadacitinib (UPA) alone and compared to other Janus kinase inhibitors (JAKis) or tumor necrosis factor inhibitors (TNFis) in patients with rheumatoid arthritis (RA).
Methods: This retrospective, non-interventional study used the OPAL dataset, derived from electronic medical records. Patients initiated UPA (N = 2624), other JAKis (baricitinib and tofacitinib [N = 925]), or TNFis (adalimumab, etanercept, certolizumab, golimumab, infliximab [N = 3540]) between May 2020 and March 2023.
Autoimmune Enteritis in an Adult With Psoriatic Arthritis, Successfully Treated With Glucocorticoids and Adalimumab.
Cureus
December 2024
Rheumatology, Rochester Regional Health, Rochester, USA.
Article Synopsis
- Autoimmune enteritis (AIE) is a rare and severe condition that mainly leads to persistent diarrhea and malnutrition, often diagnosed in infants but can occur in adults.
- A male patient in his 60s with a history of psoriasis developed intractable diarrhea despite various treatments and ultimately required total parenteral nutrition.
- After biopsies confirmed AIE, he was treated with prednisone, budesonide, and adalimumab, leading to significant improvement and normalization of his bowel habits.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!